Posted in Watchlist on Aug 22nd, 2010
JAZZ – This will likely be the last week that JAZZ tops the watchlist for a while. As we all likely know, the FDA’s Advisory Panel voted 2 Yes – 20 No to recommend the approval off JZP-6 for the treatment of severe fibromyalgia. JAZZ resumed trading in after hours on Friday, and after an [...]
We first discussed ARNA back on May 20th, back when ARNA was $2.90 a share. That is a far cry from today’s close of nearly $7 per share. Take a look at the incredible chart for ARNA over the past few months. Can ARNA maintain this momentum up to the FDA Panel on September 16th? [...]
Posted in Watchlist on Jul 25th, 2010
ARNA – Arena continues its upward momentum, temporarily breaking through $6 on Friday. How long can it continiue this trend? Will it keep advancing as it approaches is FDA Panel? September 16th is a long ways off… I have no position in ARNA, but remember this stock was $2.89 just a month ago. JAZZ – [...]
Posted in Watchlist on Jul 18th, 2010
VVUS- #1 on the watch list last week and this week is Vivus. It will be interesting to see how the market reacts to the surprise majority “No” vote. The PDUFA date is a long ways away (10/28/10), so barring any major dips I will steer clear of VVUS until closer to the PDUFA date. Last [...]
Posted in Watchlist on Jul 4th, 2010
Note: The US stock market is closed on Monday in observance of the 4th of July holiday. VVUS – Vivus remains on the weekly watchlist as activity and interest in the company should pick up this week and into next week’s FDA Panel on 7/15. For those playing the run-up, remember that the FDA releases [...]
Posted in FDA Panel, Trading Method on Jun 1st, 2010
A few weeks ago we published an article all about Arena Pharmaceuticals and its FDA PDUFA date of 10/22/10. It is worth noting that the catalyst date for ARNA may soon be bumped up by over a month, to 9/15/10. The FDA has schedule for 9/15 -9/16 an Endocrinologic and Metabolic Drugs Advisory Panel. As [...]
Posted in FDA, FDA PDUFA, Options, Run-Up Method on May 20th, 2010
Arena Pharmaceuticals Arena pharmaceuticals joins VVUS and OREX with an upcoming obesity drugs. It is clear to see that an effective an FDA approved obesity drug could be a potential gold mine. ARNA is currently trading in the low $3 range with an FDA PDUFA date of 10/22/10. Currently ARNA is trading below its 200 [...]
Twitter
Facebook
RSS
Email